Andrew Miller, PhD

Dr. Miller is a highly accomplished biopharmaceutical executive with expertise in neuropsychiatric drug development, corporate strategy, and value creation. Most recently, he was the Founder and President of R&D at Karuna Therapeutics, where he was the lead inventor of KarXT — now marketed by Bristol Myers Squibb as COBENFY® for the treatment of schizophrenia, the first novel mechanism approved in the indication in decades. He previously served as Karuna’s Chief Operating Officer, Chief Executive Officer, and as a member of its Board of Directors, guiding the company through its $14 billion acquisition by Bristol Myers Squibb in 2024. Dr. Miller was named to Time magazine’s 100 Next Generation Leaders and 100 Most Influential People in Healthcare for 2025.

Dr. Miller currently serves as Chairman of the Board of Progentos Therapeutics and a member of the Board of Montara Therapeutics and as an advisor to GV (Google Ventures), General Atlantic, Vida Ventures, Longwood Fund, and the One Mind Foundation. He holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from the University of Illinois at Urbana-Champaign.